Nanjing has taken the lead in production of medicines to treat COVID, as a locally-based pharmaceutical giant has brought about the first domestically-made, 3CL-protease, anti-COVID drug, with a projected-annual capacity to help tens of millions of people.
南京在新冠药物生产上处于领先地位，本土制药巨头推出了首款国产3CL蛋白酶抗新冠药物，预计年产能可帮助数千万人。
This past Saturday, 11 February, saw the official production launch of the Nanjing-produced COVID treatment medicine, Synopsin (先诺欣), a product of pharmaceutical behemoth, Simcere, based in Nanjing’s Jiangbei New Area.
2月11日，上周六，南京生产的新冠治疗药物先诺欣正式投产，这是制药巨头先声药业在南京江北新区的产品。
According to the State Food & Drug Administration, Synopsin (official English name not yet determined), which comes in tablet form, can be used to treat adults with a mild to moderate COVID infection.
据国家食品药品监督管理局介绍，Synopsin（官方英文名称尚未确定）为片剂形式，可用于治疗成人轻至中度新冠病毒感染。
In terms of price, Synopsin’s initial offer is ¥750 per box. But given that it falls within the scope of China’s COVID Diagnosis & Treatment Plan, Synopsin qualifies to be covered by basic provincial medical insurance until 31 March, 2023. In some cases, a patient may personally have to pay less than ¥100.
价格方面，Synopsin的首发报价为每盒750日元。但考虑到它属于中国新冠肺炎诊疗方案的范围，Synopsin有资格在2023年3月31日之前享受省级基本医疗保险。在某些情况下，患者个人支付的费用可能低于100元。
This also makes Synopsin by far the cheapest anti-COVID drug on the market.
这也使得 Synopsin 成为迄今为止市场上最便宜的抗新冠药物。
Simcere has previously stated that over a 5-day course of treatment, compared with placebo groups, the viral load of Synopsin can be reduced by more than 96 percent, against Pfizer’s Paxlovid at 86.4 percent.
先声药业此前曾表示，在5天的治疗过程中，与安慰剂组相比，Synopsin的病毒载量可降低96%以上，而辉瑞的Paxlovid则为86.4%。
Research also showed that the new drug is well tolerated in patients with mild to moderate COVID in China.
研究还表明，该新药在中国的轻至中度新冠患者中具有良好的耐受性。
During the early stages of the Synopsis rollout, priority is expected to be given to the elderly, and those with low immunity or other conditions making them susceptible to COVID.
在 Synopsis 推出的早期阶段，预计将优先考虑老年人、免疫力低下或其他容易感染新冠病毒的人。
Synopsis was reviewed and approved by the State Food and Drug Administration for conditional listing in China on 28 January, with the approval number, GYZZ H20230001, becoming the first Class 1 innovative drug approved thereby in 2023.
1月28日，该药获得国家食品药品监督管理局附条件上市批准，批准文号为国药中药H20230001，成为2023年首个获批的一类创新药。
It’s been a very quick turnaround to get to where we are today. Industry insiders are pointing to the recent and rapid upgrade of China’s bio pharmaceutical industry as responsible for Synopsin going from project initiation to approval in only 14 months.
我们经历了一个非常快的转变才达到今天的水平。业内人士指出，近期中国生物医药产业快速升级，Synopsin从立项到获批仅用了14个月。
Interested readers may enjoy a video of the Synopsis production process, available in a media report by the Yangtze Evening News via this link.
有兴趣的读者可以通过此链接观看扬子晚报媒体报道中的剧情简介制作过程的视频。
But don’t go looking for the new wonder dug in your local pharmacy any time soon. The Nanjinger today visited a branch of Simcere this afternoon and received blank looks from staff in response to requests for the new medicine.
但不要很快就去当地药房寻找新的奇迹。今天下午，《南京人》记者来到先声药业的一家分店，看到工作人员对新药的询问，一脸茫然。
